Compugen Ltd (CGEN.OQ)
3.65USD
22 Jun 2018
-- (--)
$3.65
--
--
--
--
49,671
$5.00
$2.25
About
Overall
| Beta: | 0.65 |
| Market Cap(Mil.): | $175.64 |
| Shares Outstanding(Mil.): | 51.13 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CGEN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 82.81 | 32.74 |
| EPS (TTM): | -0.67 | -- | -- |
| ROI: | -52.36 | 2.00 | 14.38 |
| ROE: | -54.94 | 3.49 | 16.08 |
BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018
* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Deals of the day-Mergers and acquisitions
April 2 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ** General Electric Co's healthcare unit said it would sell its information technology business to private equity firm Veritas Capital for $1.05 billion in cash as it sharpens its focus on smart diagnostics and connected devices. ** ReNew Power, backed by Goldman Sachs and Canada Pension Plan Investment Board (CPPIB), said it has acquired Ostro Energy Private Ltd, backed by London-bas
BRIEF-Compugen Announces Exclusive License Agreement With Medimmune
* CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES Source text (https://bit.ly/2GsywkV) Further company coverage: (Reuters.Brief@thomsonreuters.com)
Compugen, AstraZeneca unit in cancer drug development deal
JERUSALEM Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds).
Compugen, AstraZeneca unit in cancer drug development deal
JERUSALEM, April 2 Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million.
BRIEF-Compugen Reports Q4 Loss Per Share Of $0.18
* COMPUGEN - AS OF DEC 31, 2017, CASH, CASH RELATED ACCOUNTS, SHORT-TERM AND LONG-TERM BANK DEPOSITS TOTALED $30.4 MILLION, COMPARED WITH $61.5 MILLION LAST YEAR Source text for Eikon: Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $36.51 | +0.21 |
| Roche Holding Ltd. (ROG.S) | CHF216.45 | -- |
| Roche Holding Ltd. (RO.S) | CHF223.00 | -0.60 |
| Abbott Laboratories (ABT.N) | $61.94 | +0.19 |
| Bristol-Myers Squibb Co (BMY.N) | $55.14 | +1.20 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $919.60 | -- |
| Amgen, Inc. (AMGN.OQ) | $185.15 | -- |
| Quest Diagnostics Inc (DGX.N) | $112.04 | +0.86 |
Estimates